US 12,263,176 B2
Pharmaceutical liquid compositions of meloxicam
Ashish Anilrao Dubewar, Hyderabad (IN); Sumitra Ashokkumar Pillai, Hyderabad (IN); Pradeep Kumar Kare, Hyderabad (IN); Kumar Swamy Ummiti, Hyderabad (IN); Shanker Mamidi, Nalgonda (IN); and Raghavender Rao Kategher, Vikarabad (IN)
Assigned to SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed by SLAYBACK PHARMA LLC, Princeton, NJ (US)
Filed on Dec. 15, 2023, as Appl. No. 18/542,163.
Application 18/542,163 is a continuation of application No. 17/725,772, filed on Apr. 21, 2022, abandoned.
Application 17/725,772 is a continuation in part of application No. 17/368,367, filed on Jul. 6, 2021, abandoned.
Claims priority of application No. 202041028641 (IN), filed on Jul. 6, 2020.
Prior Publication US 2024/0139204 A1, May 2, 2024
Int. Cl. A61K 31/5415 (2006.01); A61K 47/10 (2017.01); A61K 47/30 (2006.01); A61K 47/38 (2006.01); A61K 47/40 (2006.01); A61K 47/44 (2017.01)
CPC A61K 31/5415 (2013.01) [A61K 47/10 (2013.01); A61K 47/30 (2013.01); A61K 47/38 (2013.01); A61K 47/40 (2013.01); A61K 47/44 (2013.01)] 14 Claims
 
1. An injectable solution suitable for parenteral administration comprising:
(a) about 30 mg/mL of meloxicam,
(b) one or more pharmaceutically acceptable solvents; and
(c) a solubilizer, wherein the solubilizer comprises a combination of meglumine and a cyclodextrin derivative,
wherein the concentration of meglumine is between 10 mg/mL and 50 mg/mL;
wherein the concentration of the cyclodextrin derivative is from about 5 mg/mL to about 250 mg/mL;
wherein the solution is a ready-to-use formulation, and
wherein the solution is stable and remains clear when stored for 6 months at 40° C./75% RH, and.